Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy.

Heller DR, Chiuzan C, Taub RN, Leinwand JC, Greene AM, Bates GE, Chabot JA, Kluger MD.

Ann Surg Oncol. 2017 Dec;24(13):3818-3824. doi: 10.1245/s10434-017-6106-x. Epub 2017 Oct 12.

PMID:
29027138
2.

The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M.

Ann Surg Oncol. 2016 May;23(5):1468-73. doi: 10.1245/s10434-015-4962-9. Epub 2015 Nov 16.

PMID:
26572754
3.
4.

Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.

Ann Surg Oncol. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12.

PMID:
19082859
5.

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.

Vassos N, Förtsch T, Aladashvili A, Hohenberger W, Croner RS.

World J Surg Oncol. 2016 Feb 24;14(1):42. doi: 10.1186/s12957-016-0804-x.

6.

The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S.

Ann Surg Oncol. 2013 Apr;20(4):1093-100. doi: 10.1245/s10434-012-2845-x. Epub 2013 Mar 2.

PMID:
23456386
7.

Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA.

Ann Surg Oncol. 2014 Apr;21(4):1159-65. doi: 10.1245/s10434-013-3358-y. Epub 2013 Dec 10.

8.

Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.

Le Roy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, Benhaim L, Malka D, Ducreux M, Elias D, Goéré D.

Ann Surg Oncol. 2017 Nov;24(12):3640-3646. doi: 10.1245/s10434-017-6033-x. Epub 2017 Aug 28.

PMID:
28849389
9.

The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.

El Halabi H, Gushchin V, Francis J, Athas N, Macdonald R, Nieroda C, Studeman K, Sardi A.

Ann Surg Oncol. 2012 Jan;19(1):110-4. doi: 10.1245/s10434-011-1840-y. Epub 2011 Jun 24.

PMID:
21701929
10.

Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.

Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ, Parrilla P.

Ann Surg Oncol. 2014 Jul;21(7):2383-9. doi: 10.1245/s10434-014-3599-4. Epub 2014 Mar 6.

PMID:
24599409
11.

Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.

Verma V, Sleightholm RL, Rusthoven CG, Koshy M, Sher DJ, Grover S, Simone CB 2nd.

Ann Surg Oncol. 2018 Jul;25(7):2018-2026. doi: 10.1245/s10434-018-6499-1. Epub 2018 May 2.

PMID:
29721724
12.

Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.

Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S.

Ann Surg Oncol. 2014 May;21(5):1480-6. doi: 10.1245/s10434-013-3341-7. Epub 2013 Oct 25.

PMID:
24158467
13.

Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Baratti D, Vaira M, Kusamura S, D'Amico S, Balestra MR, Cioppa T, Mingrone E, De Simone M, Deraco M.

Eur J Surg Oncol. 2010 Nov;36(11):1047-53. doi: 10.1016/j.ejso.2010.08.130. Epub 2010 Sep 15.

PMID:
20832234
14.

Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Jimenez W, Sardi A, Nieroda C, Sittig M, Milovanov V, Nunez M, Aydin N, Gushchin V.

Ann Surg Oncol. 2014 Dec;21(13):4218-25. doi: 10.1245/s10434-014-3869-1. Epub 2014 Jul 2.

PMID:
24986239
15.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.

Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM.

Ann Surg Oncol. 2015 May;22(5):1686-93. doi: 10.1245/s10434-014-3978-x. Epub 2014 Aug 15. Review.

PMID:
25124472
16.

Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.

Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E.

J Surg Oncol. 2012 Aug 1;106(2):197-203. doi: 10.1002/jso.23062. Epub 2012 Feb 13.

PMID:
22331814
17.

Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.

Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, Zureikat AH, Holtzman MP, Pingpank J, Ahrendt S, Zeh HJ, Bartlett DL, Choudry HA.

Ann Surg Oncol. 2015 May;22(5):1673-9. doi: 10.1245/s10434-014-4111-x. Epub 2014 Nov 7.

PMID:
25377640
18.

Current trends in the management of malignant peritoneal mesothelioma.

Miura JT, Johnston FM, Gamblin TC, Turaga KK.

Ann Surg Oncol. 2014 Nov;21(12):3947-53. doi: 10.1245/s10434-014-3803-6. Epub 2014 May 20.

PMID:
24841356
19.

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.

Ann Surg Oncol. 2007 Oct;14(10):2790-7. Epub 2007 Jul 28.

PMID:
17661150
20.

The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.

Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, Ruiz-Pardo J, Nieto A, Parrilla JJ, Parrilla P.

Ann Surg Oncol. 2015 Mar;22(3):987-93. doi: 10.1245/s10434-014-4049-z. Epub 2014 Sep 12.

PMID:
25212832

Supplemental Content

Support Center